Positive Results Reported From Phase 2 Study of SRP-5051 in DMD

Positive Results Reported From Phase 2 Study of SRP-5051 in DMD

293489

Positive Results Reported From Phase 2 Study of SRP-5051 in DMD

Sarepta Therapeutics has announced positive results from a global study evaluating its investigational treatment SRP-5051 in people with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Results from part A of the study found the 30 mg/kg monthly dose resulted in eight times the dystrophin production at three months compared to Exondys 51 (eteplirsen), dosed weekly for six months. Treatment with this dose also led to 18 times the exon skipping at this…

You must be logged in to read/download the full post.